Gapping up
In reaction to earnings/guidance:
- FLXN +9.7%, KPTI +6.7% (prelim Q2 sdales for XPOVIO), XYL +4%, JPM +1.5%, FAST +1.5%
Other news:
- IMV +159.7% (provides update on vaccine development for COVID-19 prevention)
- VNRX +74.6% (comments on clinical trials results for its novel COVID-19 triage test)
- RIGL +20.8% (Rigel Pharma and Imperial College London initiates two-stage trial to evaluate the efficacy of fostamatinib for the treatment of COVID-19 pneumonia)
- CYAD +12.4% (receives FDA clearance of IND application for CYAD-211)
- BPMC +9.6% (to collaborate with Roche (RHHBY) to develop and commercialize Pralsetinib)
- ALT +8.2% (prices offering of $115 mln of common stock and pre-funded warrants)
- VNDA +5.6% (receives FDA authorization for protocol for the use of tradipitant for gastroparesis)
- APRN +4% (peer HelloFresh reported better than expected earnings)
- BA +2.6% (awarded $22.9 bln Air Force contract)
- SPAQ +2.6% (Fisker, which is being acquired by SPAQ, reportedly in talks to use Volkswagen platform to power its SUV, according to The Verge)
- IMMU +2.1% (expands collaboration with Roche to evaluate Trodelvy with Tecentriq)
- CDXC +1.8% (external research program achieves 200th material transfer agreement for Niagen Research)
- EW +1.3% (ABT and EW settle patent cases)
Analyst comments:
- MTDR +6.6% (upgraded to Buy from Neutral at MKM Partners)
- HBI +5.6% (upgraded to Outperform from Neutral at Credit Suisse)
- TSM +2.4% (upgraded to Buy from Outperform at CLSA)
- HOG +2.1% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- HMC +1.5% (upgraded to Buy from Underperform at CLSA)
- NVDA +1.5% (target raised to $475 at Cowen)
- MA +1.3% (initiated with a Buy at Goldman and added to Conviction Buy List)
- V +1% (initiated with a Buy at Goldman)